CytoDyn Inc (OTCMKTS: CYDY) On Watch as Ambitious
Post# of 154115
(Total Views: 810)
Posted On: 05/05/2023 11:25:31 AM
CytoDyn Inc (OTCMKTS: CYDY) On Watch as Ambitious New President Implements Big Plans for Leronlimab (PRO 140) & CytoDyn (NASH, HIV, Cancer Solid Tumors and more)
buzzondabeach@gmail.com'
ByBoe Rimes
MAR 4, 2023 CYDY
2,043
CytoDyn Inc (OTCMKTS: CYDY) is among the most exciting stories in small caps, a well-known highly liquid biotech trading just over historical lows with a long history of powerful moves at much higher prices sits just over $0.30 per share and is averaging about a million dollars in dollar volume per day. CYDY ran to well over $10 per share in 2020 but the stock was decimated when Citron stepped in, killed the momentum and destoyed the run completely. Now with CYDY trading very near itsr historical lows and an amitious new CEO at the helm who took over the job from Nader who is currently under multiple investigations, CYDY is at the top of specuators watch lists here. Historically CYDY has not traded flat for long and was trading at much higher prices. New CEO Cyrus Arman is implementing an ambitious plan to move Cytodyn forward including removing the FDA clinical holds placed on its HIV and COVID-19 programs. In a real show of confidence in CytoDyn, Cyrus Arman also recently invested $100,000 of his own money into the Company. Also Dr. Welch has taken shares instead of money another big show of confidence in CytoDyn and its future, all of which is not positive for the very significant short position currently in the stock.
NASH and solid tumors, each represent multi-billion dollar valuation opportunities for CytoDyn, and management believes Leronlimab has the potential to become the standard of care in these indications in the future. The Company plans to advance its NASH program to a Phase 2b or Phase 2b/3 trial for steatosis and liver fibrosis associated with NASH this follows the highly encouraging 700 mg NASH data, contining its Phase 2 program for metastatic triple-negative breast cancer with current standard of care, explore a Phase 2 colon cancer trial with current standard of care, and explore other solid tumor indications, as well as evaluating the feasibility and timelines for the HIV BLA resubmission and explore other cancer and immunologic indications for leronlimab. We will be updating on CYDY when more details emerge so make sure you are subscribed to wwallstreet.com by entering your email below.
CytoDyn Inc (OTCMKTS: CYDY) mission is to enhance the lives of patients with life-threatening diseases and alleviate human suffering and improve patients’ quality of life through innovation and collaboration. The Company is in late-stage clinical development of leronlimab, a CCR5 receptor antagonist, to be used as a platform drug for various therapeutic indications, including NASH, NASH/HIV, oncology, and HIV and even cancer. Cytodyn has been building a valuable intellectual property portfolio and now has a total of 9 patents in the US and 20 pending patents pending, internationally the Company holds 35 patents and has 51 patents pending.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have
https://wwallstreet.com/2023/03/04/cytodyn-in...-and-more/
buzzondabeach@gmail.com'
ByBoe Rimes
MAR 4, 2023 CYDY
2,043
CytoDyn Inc (OTCMKTS: CYDY) is among the most exciting stories in small caps, a well-known highly liquid biotech trading just over historical lows with a long history of powerful moves at much higher prices sits just over $0.30 per share and is averaging about a million dollars in dollar volume per day. CYDY ran to well over $10 per share in 2020 but the stock was decimated when Citron stepped in, killed the momentum and destoyed the run completely. Now with CYDY trading very near itsr historical lows and an amitious new CEO at the helm who took over the job from Nader who is currently under multiple investigations, CYDY is at the top of specuators watch lists here. Historically CYDY has not traded flat for long and was trading at much higher prices. New CEO Cyrus Arman is implementing an ambitious plan to move Cytodyn forward including removing the FDA clinical holds placed on its HIV and COVID-19 programs. In a real show of confidence in CytoDyn, Cyrus Arman also recently invested $100,000 of his own money into the Company. Also Dr. Welch has taken shares instead of money another big show of confidence in CytoDyn and its future, all of which is not positive for the very significant short position currently in the stock.
NASH and solid tumors, each represent multi-billion dollar valuation opportunities for CytoDyn, and management believes Leronlimab has the potential to become the standard of care in these indications in the future. The Company plans to advance its NASH program to a Phase 2b or Phase 2b/3 trial for steatosis and liver fibrosis associated with NASH this follows the highly encouraging 700 mg NASH data, contining its Phase 2 program for metastatic triple-negative breast cancer with current standard of care, explore a Phase 2 colon cancer trial with current standard of care, and explore other solid tumor indications, as well as evaluating the feasibility and timelines for the HIV BLA resubmission and explore other cancer and immunologic indications for leronlimab. We will be updating on CYDY when more details emerge so make sure you are subscribed to wwallstreet.com by entering your email below.
CytoDyn Inc (OTCMKTS: CYDY) mission is to enhance the lives of patients with life-threatening diseases and alleviate human suffering and improve patients’ quality of life through innovation and collaboration. The Company is in late-stage clinical development of leronlimab, a CCR5 receptor antagonist, to be used as a platform drug for various therapeutic indications, including NASH, NASH/HIV, oncology, and HIV and even cancer. Cytodyn has been building a valuable intellectual property portfolio and now has a total of 9 patents in the US and 20 pending patents pending, internationally the Company holds 35 patents and has 51 patents pending.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have
https://wwallstreet.com/2023/03/04/cytodyn-in...-and-more/
(0)
(0)